img

Global Quadrivalent Meningococcal Vaccine Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Quadrivalent Meningococcal Vaccine Market Insights, Forecast to 2034

The meningococcal quadrivalent vaccine protects against 4 types of meningococcustypes A, C, Y, and W.
Global Quadrivalent Meningococcal Vaccine market is expected to reach to US$ 174 million in 2023, with a positive growth of %, compared with US$ 185 million in 2024 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Quadrivalent Meningococcal Vaccine industry is evaluated to reach US$ 245.2 million in 2034. The CAGR will be 5.9% during 2023 to 2034.
Many countries have implemented meningococcal vaccination programs, especially targeting high-risk groups such as infants, adolescents and university students. Inclusion or recommendation of quadrivalent meningococcal vaccines in national immunization schedules can significantly influence the market demand.
Report Covers
This report presents an overview of global Quadrivalent Meningococcal Vaccine market from 2018 to 2034, aiming to help readers to get a comprehensive understanding of global Quadrivalent Meningococcal Vaccine market with multiple angles. Items like regional sales, revenue from 2018 to 2034 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2023 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2034 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Sanofi-Pasteur
Walvax
Chengdu Kanghua Biological Products Co., Ltd.
Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
Beijing Institute of Biological Products Co., Ltd.
CanSino Biological Co., Ltd.
Hualan Biological Vaccine Co., Ltd.
Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
Segment by Type
Polysaccharide Vaccine
Conjugate Vaccine

Segment by Application


Hospital
Clinic

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2034
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Quadrivalent Meningococcal Vaccine plant distribution, commercial date of Quadrivalent Meningococcal Vaccine, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2034 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2034 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2034 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2034
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2034 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2034
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2034 in China. Product sales and revenue analysis of China from 2018 to 2034
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2034 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2034
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2034 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2034.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Quadrivalent Meningococcal Vaccine introduction, etc. Quadrivalent Meningococcal Vaccine Sales, Revenue, Price and Gross Margin of each company from 2018 to 2023
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Quadrivalent Meningococcal Vaccine
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Quadrivalent Meningococcal Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Quadrivalent Meningococcal Vaccine Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Polysaccharide Vaccine
1.2.3 Conjugate Vaccine
1.3 Market by Application
1.3.1 Global Quadrivalent Meningococcal Vaccine Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Quadrivalent Meningococcal Vaccine Sales Estimates and Forecasts 2018-2034
2.2 Global Quadrivalent Meningococcal Vaccine Revenue by Region
2.2.1 Global Quadrivalent Meningococcal Vaccine Revenue by Region: 2018 VS 2024 VS 2034
2.2.2 Global Quadrivalent Meningococcal Vaccine Revenue by Region (2018-2023)
2.2.3 Global Quadrivalent Meningococcal Vaccine Revenue by Region (2024-2034)
2.2.4 Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Region (2018-2034)
2.3 Global Quadrivalent Meningococcal Vaccine Sales Estimates and Forecasts 2018-2034
2.4 Global Quadrivalent Meningococcal Vaccine Sales by Region
2.4.1 Global Quadrivalent Meningococcal Vaccine Sales by Region: 2018 VS 2024 VS 2034
2.4.2 Global Quadrivalent Meningococcal Vaccine Sales by Region (2018-2023)
2.4.3 Global Quadrivalent Meningococcal Vaccine Sales by Region (2024-2034)
2.4.4 Global Quadrivalent Meningococcal Vaccine Sales Market Share by Region (2018-2034)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Quadrivalent Meningococcal Vaccine Sales by Manufacturers
3.1.1 Global Quadrivalent Meningococcal Vaccine Sales by Manufacturers (2018-2023)
3.1.2 Global Quadrivalent Meningococcal Vaccine Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Quadrivalent Meningococcal Vaccine in 2024
3.2 Global Quadrivalent Meningococcal Vaccine Revenue by Manufacturers
3.2.1 Global Quadrivalent Meningococcal Vaccine Revenue by Manufacturers (2018-2023)
3.2.2 Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Quadrivalent Meningococcal Vaccine Revenue in 2024
3.3 Global Key Players of Quadrivalent Meningococcal Vaccine, Industry Ranking, 2021 VS 2024 VS 2023
3.4 Global Quadrivalent Meningococcal Vaccine Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Quadrivalent Meningococcal Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Quadrivalent Meningococcal Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Quadrivalent Meningococcal Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Quadrivalent Meningococcal Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Quadrivalent Meningococcal Vaccine Sales by Type
4.1.1 Global Quadrivalent Meningococcal Vaccine Historical Sales by Type (2018-2023)
4.1.2 Global Quadrivalent Meningococcal Vaccine Forecasted Sales by Type (2024-2034)
4.1.3 Global Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2034)
4.2 Global Quadrivalent Meningococcal Vaccine Revenue by Type
4.2.1 Global Quadrivalent Meningococcal Vaccine Historical Revenue by Type (2018-2023)
4.2.2 Global Quadrivalent Meningococcal Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Quadrivalent Meningococcal Vaccine Price by Type
4.3.1 Global Quadrivalent Meningococcal Vaccine Price by Type (2018-2023)
4.3.2 Global Quadrivalent Meningococcal Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Quadrivalent Meningococcal Vaccine Sales by Application
5.1.1 Global Quadrivalent Meningococcal Vaccine Historical Sales by Application (2018-2023)
5.1.2 Global Quadrivalent Meningococcal Vaccine Forecasted Sales by Application (2024-2034)
5.1.3 Global Quadrivalent Meningococcal Vaccine Sales Market Share by Application (2018-2034)
5.2 Global Quadrivalent Meningococcal Vaccine Revenue by Application
5.2.1 Global Quadrivalent Meningococcal Vaccine Historical Revenue by Application (2018-2023)
5.2.2 Global Quadrivalent Meningococcal Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Quadrivalent Meningococcal Vaccine Price by Application
5.3.1 Global Quadrivalent Meningococcal Vaccine Price by Application (2018-2023)
5.3.2 Global Quadrivalent Meningococcal Vaccine Price Forecast by Application (2024-2034)
6 US & Canada
6.1 US & Canada Quadrivalent Meningococcal Vaccine Market Size by Type
6.1.1 US & Canada Quadrivalent Meningococcal Vaccine Sales by Type (2018-2034)
6.1.2 US & Canada Quadrivalent Meningococcal Vaccine Revenue by Type (2018-2034)
6.2 US & Canada Quadrivalent Meningococcal Vaccine Market Size by Application
6.2.1 US & Canada Quadrivalent Meningococcal Vaccine Sales by Application (2018-2034)
6.2.2 US & Canada Quadrivalent Meningococcal Vaccine Revenue by Application (2018-2034)
6.3 US & Canada Quadrivalent Meningococcal Vaccine Market Size by Country
6.3.1 US & Canada Quadrivalent Meningococcal Vaccine Revenue by Country: 2018 VS 2024 VS 2034
6.3.2 US & Canada Quadrivalent Meningococcal Vaccine Sales by Country (2018-2034)
6.3.3 US & Canada Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2034)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Quadrivalent Meningococcal Vaccine Market Size by Type
7.1.1 Europe Quadrivalent Meningococcal Vaccine Sales by Type (2018-2034)
7.1.2 Europe Quadrivalent Meningococcal Vaccine Revenue by Type (2018-2034)
7.2 Europe Quadrivalent Meningococcal Vaccine Market Size by Application
7.2.1 Europe Quadrivalent Meningococcal Vaccine Sales by Application (2018-2034)
7.2.2 Europe Quadrivalent Meningococcal Vaccine Revenue by Application (2018-2034)
7.3 Europe Quadrivalent Meningococcal Vaccine Market Size by Country
7.3.1 Europe Quadrivalent Meningococcal Vaccine Revenue by Country: 2018 VS 2024 VS 2034
7.3.2 Europe Quadrivalent Meningococcal Vaccine Sales by Country (2018-2034)
7.3.3 Europe Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2034)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Quadrivalent Meningococcal Vaccine Market Size
8.1.1 China Quadrivalent Meningococcal Vaccine Sales (2018-2034)
8.1.2 China Quadrivalent Meningococcal Vaccine Revenue (2018-2034)
8.2 China Quadrivalent Meningococcal Vaccine Market Size by Application
8.2.1 China Quadrivalent Meningococcal Vaccine Sales by Application (2018-2034)
8.2.2 China Quadrivalent Meningococcal Vaccine Revenue by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Quadrivalent Meningococcal Vaccine Market Size by Type
9.1.1 Asia Quadrivalent Meningococcal Vaccine Sales by Type (2018-2034)
9.1.2 Asia Quadrivalent Meningococcal Vaccine Revenue by Type (2018-2034)
9.2 Asia Quadrivalent Meningococcal Vaccine Market Size by Application
9.2.1 Asia Quadrivalent Meningococcal Vaccine Sales by Application (2018-2034)
9.2.2 Asia Quadrivalent Meningococcal Vaccine Revenue by Application (2018-2034)
9.3 Asia Quadrivalent Meningococcal Vaccine Sales by Region
9.3.1 Asia Quadrivalent Meningococcal Vaccine Revenue by Region: 2018 VS 2024 VS 2034
9.3.2 Asia Quadrivalent Meningococcal Vaccine Revenue by Region (2018-2034)
9.3.3 Asia Quadrivalent Meningococcal Vaccine Sales by Region (2018-2034)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Market Size by Type
10.1.1 Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Sales by Type (2018-2034)
10.1.2 Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue by Type (2018-2034)
10.2 Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Market Size by Application
10.2.1 Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Sales by Application (2018-2034)
10.2.2 Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue by Application (2018-2034)
10.3 Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Sales by Country
10.3.1 Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue by Country: 2018 VS 2024 VS 2034
10.3.2 Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2034)
10.3.3 Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Sales by Country (2018-2034)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Sanofi-Pasteur
11.1.1 Sanofi-Pasteur Company Information
11.1.2 Sanofi-Pasteur Overview
11.1.3 Sanofi-Pasteur Quadrivalent Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Sanofi-Pasteur Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Sanofi-Pasteur Recent Developments
11.2 Walvax
11.2.1 Walvax Company Information
11.2.2 Walvax Overview
11.2.3 Walvax Quadrivalent Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 Walvax Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Walvax Recent Developments
11.3 Chengdu Kanghua Biological Products Co., Ltd.
11.3.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
11.3.2 Chengdu Kanghua Biological Products Co., Ltd. Overview
11.3.3 Chengdu Kanghua Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Chengdu Kanghua Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Chengdu Kanghua Biological Products Co., Ltd. Recent Developments
11.4 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd.
11.4.1 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Company Information
11.4.2 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Overview
11.4.3 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Recent Developments
11.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd.
11.5.1 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Company Information
11.5.2 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Overview
11.5.3 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Recent Developments
11.6 Beijing Institute of Biological Products Co., Ltd.
11.6.1 Beijing Institute of Biological Products Co., Ltd. Company Information
11.6.2 Beijing Institute of Biological Products Co., Ltd. Overview
11.6.3 Beijing Institute of Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Beijing Institute of Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Beijing Institute of Biological Products Co., Ltd. Recent Developments
11.7 CanSino Biological Co., Ltd.
11.7.1 CanSino Biological Co., Ltd. Company Information
11.7.2 CanSino Biological Co., Ltd. Overview
11.7.3 CanSino Biological Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 CanSino Biological Co., Ltd. Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 CanSino Biological Co., Ltd. Recent Developments
11.8 Hualan Biological Vaccine Co., Ltd.
11.8.1 Hualan Biological Vaccine Co., Ltd. Company Information
11.8.2 Hualan Biological Vaccine Co., Ltd. Overview
11.8.3 Hualan Biological Vaccine Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Hualan Biological Vaccine Co., Ltd. Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Hualan Biological Vaccine Co., Ltd. Recent Developments
11.9 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd.
11.9.1 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Company Information
11.9.2 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Overview
11.9.3 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Quadrivalent Meningococcal Vaccine Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Quadrivalent Meningococcal Vaccine Industry Chain Analysis
12.2 Quadrivalent Meningococcal Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Quadrivalent Meningococcal Vaccine Production Mode & Process
12.4 Quadrivalent Meningococcal Vaccine Sales and Marketing
12.4.1 Quadrivalent Meningococcal Vaccine Sales Channels
12.4.2 Quadrivalent Meningococcal Vaccine Distributors
12.5 Quadrivalent Meningococcal Vaccine Customers
13 Market Dynamics
13.1 Quadrivalent Meningococcal Vaccine Industry Trends
13.2 Quadrivalent Meningococcal Vaccine Market Drivers
13.3 Quadrivalent Meningococcal Vaccine Market Challenges
13.4 Quadrivalent Meningococcal Vaccine Market Restraints
14 Key Findings in The Global Quadrivalent Meningococcal Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Quadrivalent Meningococcal Vaccine Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Polysaccharide Vaccine
Table 3. Major Manufacturers of Conjugate Vaccine
Table 4. Global Quadrivalent Meningococcal Vaccine Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 5. Global Quadrivalent Meningococcal Vaccine Revenue Grow Rate (CAGR) by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Quadrivalent Meningococcal Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global Quadrivalent Meningococcal Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 8. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Region (2018-2023)
Table 9. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Region (2024-2034)
Table 10. Global Quadrivalent Meningococcal Vaccine Sales Grow Rate (CAGR) by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 11. Global Quadrivalent Meningococcal Vaccine Sales by Region (2018-2023) & (K Units)
Table 12. Global Quadrivalent Meningococcal Vaccine Sales by Region (2024-2034) & (K Units)
Table 13. Global Quadrivalent Meningococcal Vaccine Sales Market Share by Region (2018-2023)
Table 14. Global Quadrivalent Meningococcal Vaccine Sales Market Share by Region (2024-2034)
Table 15. Global Quadrivalent Meningococcal Vaccine Sales by Manufacturers (2018-2023) & (K Units)
Table 16. Global Quadrivalent Meningococcal Vaccine Sales Share by Manufacturers (2018-2023)
Table 17. Global Quadrivalent Meningococcal Vaccine Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 18. Global Quadrivalent Meningococcal Vaccine Revenue Share by Manufacturers (2018-2023)
Table 19. Global Key Players of Quadrivalent Meningococcal Vaccine, Industry Ranking, 2021 VS 2024 VS 2023
Table 20. Quadrivalent Meningococcal Vaccine Price by Manufacturers 2018-2023 (US$/Unit)
Table 21. Global Quadrivalent Meningococcal Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Quadrivalent Meningococcal Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Quadrivalent Meningococcal Vaccine as of 2024)
Table 23. Global Key Manufacturers of Quadrivalent Meningococcal Vaccine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Quadrivalent Meningococcal Vaccine, Product Offered and Application
Table 25. Global Key Manufacturers of Quadrivalent Meningococcal Vaccine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Quadrivalent Meningococcal Vaccine Sales by Type (2018-2023) & (K Units)
Table 28. Global Quadrivalent Meningococcal Vaccine Sales by Type (2024-2034) & (K Units)
Table 29. Global Quadrivalent Meningococcal Vaccine Sales Share by Type (2018-2023)
Table 30. Global Quadrivalent Meningococcal Vaccine Sales Share by Type (2024-2034)
Table 31. Global Quadrivalent Meningococcal Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 32. Global Quadrivalent Meningococcal Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Quadrivalent Meningococcal Vaccine Revenue Share by Type (2018-2023)
Table 34. Global Quadrivalent Meningococcal Vaccine Revenue Share by Type (2024-2034)
Table 35. Quadrivalent Meningococcal Vaccine Price by Type (2018-2023) & (US$/Unit)
Table 36. Global Quadrivalent Meningococcal Vaccine Price Forecast by Type (2024-2034) & (US$/Unit)
Table 37. Global Quadrivalent Meningococcal Vaccine Sales by Application (2018-2023) & (K Units)
Table 38. Global Quadrivalent Meningococcal Vaccine Sales by Application (2024-2034) & (K Units)
Table 39. Global Quadrivalent Meningococcal Vaccine Sales Share by Application (2018-2023)
Table 40. Global Quadrivalent Meningococcal Vaccine Sales Share by Application (2024-2034)
Table 41. Global Quadrivalent Meningococcal Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 42. Global Quadrivalent Meningococcal Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Quadrivalent Meningococcal Vaccine Revenue Share by Application (2018-2023)
Table 44. Global Quadrivalent Meningococcal Vaccine Revenue Share by Application (2024-2034)
Table 45. Quadrivalent Meningococcal Vaccine Price by Application (2018-2023) & (US$/Unit)
Table 46. Global Quadrivalent Meningococcal Vaccine Price Forecast by Application (2024-2034) & (US$/Unit)
Table 47. US & Canada Quadrivalent Meningococcal Vaccine Sales by Type (2018-2023) & (K Units)
Table 48. US & Canada Quadrivalent Meningococcal Vaccine Sales by Type (2024-2034) & (K Units)
Table 49. US & Canada Quadrivalent Meningococcal Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 50. US & Canada Quadrivalent Meningococcal Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 51. US & Canada Quadrivalent Meningococcal Vaccine Sales by Application (2018-2023) & (K Units)
Table 52. US & Canada Quadrivalent Meningococcal Vaccine Sales by Application (2024-2034) & (K Units)
Table 53. US & Canada Quadrivalent Meningococcal Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 54. US & Canada Quadrivalent Meningococcal Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 55. US & Canada Quadrivalent Meningococcal Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 56. US & Canada Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 57. US & Canada Quadrivalent Meningococcal Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 58. US & Canada Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023) & (K Units)
Table 59. US & Canada Quadrivalent Meningococcal Vaccine Sales by Country (2024-2034) & (K Units)
Table 60. Europe Quadrivalent Meningococcal Vaccine Sales by Type (2018-2023) & (K Units)
Table 61. Europe Quadrivalent Meningococcal Vaccine Sales by Type (2024-2034) & (K Units)
Table 62. Europe Quadrivalent Meningococcal Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 63. Europe Quadrivalent Meningococcal Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 64. Europe Quadrivalent Meningococcal Vaccine Sales by Application (2018-2023) & (K Units)
Table 65. Europe Quadrivalent Meningococcal Vaccine Sales by Application (2024-2034) & (K Units)
Table 66. Europe Quadrivalent Meningococcal Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 67. Europe Quadrivalent Meningococcal Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 68. Europe Quadrivalent Meningococcal Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 69. Europe Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 70. Europe Quadrivalent Meningococcal Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 71. Europe Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023) & (K Units)
Table 72. Europe Quadrivalent Meningococcal Vaccine Sales by Country (2024-2034) & (K Units)
Table 73. China Quadrivalent Meningococcal Vaccine Sales by Type (2018-2023) & (K Units)
Table 74. China Quadrivalent Meningococcal Vaccine Sales by Type (2024-2034) & (K Units)
Table 75. China Quadrivalent Meningococcal Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 76. China Quadrivalent Meningococcal Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 77. China Quadrivalent Meningococcal Vaccine Sales by Application (2018-2023) & (K Units)
Table 78. China Quadrivalent Meningococcal Vaccine Sales by Application (2024-2034) & (K Units)
Table 79. China Quadrivalent Meningococcal Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 80. China Quadrivalent Meningococcal Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 81. Asia Quadrivalent Meningococcal Vaccine Sales by Type (2018-2023) & (K Units)
Table 82. Asia Quadrivalent Meningococcal Vaccine Sales by Type (2024-2034) & (K Units)
Table 83. Asia Quadrivalent Meningococcal Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 84. Asia Quadrivalent Meningococcal Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 85. Asia Quadrivalent Meningococcal Vaccine Sales by Application (2018-2023) & (K Units)
Table 86. Asia Quadrivalent Meningococcal Vaccine Sales by Application (2024-2034) & (K Units)
Table 87. Asia Quadrivalent Meningococcal Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 88. Asia Quadrivalent Meningococcal Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 89. Asia Quadrivalent Meningococcal Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 90. Asia Quadrivalent Meningococcal Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 91. Asia Quadrivalent Meningococcal Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 92. Asia Quadrivalent Meningococcal Vaccine Sales by Region (2018-2023) & (K Units)
Table 93. Asia Quadrivalent Meningococcal Vaccine Sales by Region (2024-2034) & (K Units)
Table 94. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Sales by Type (2018-2023) & (K Units)
Table 95. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Sales by Type (2024-2034) & (K Units)
Table 96. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 97. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 98. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Sales by Application (2018-2023) & (K Units)
Table 99. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Sales by Application (2024-2034) & (K Units)
Table 100. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 101. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 102. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 103. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 104. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 105. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Sales by Country (2018-2023) & (K Units)
Table 106. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Sales by Country (2024-2034) & (K Units)
Table 107. Sanofi-Pasteur Company Information
Table 108. Sanofi-Pasteur Description and Major Businesses
Table 109. Sanofi-Pasteur Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. Sanofi-Pasteur Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Sanofi-Pasteur Recent Developments
Table 112. Walvax Company Information
Table 113. Walvax Description and Major Businesses
Table 114. Walvax Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. Walvax Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Walvax Recent Developments
Table 117. Chengdu Kanghua Biological Products Co., Ltd. Company Information
Table 118. Chengdu Kanghua Biological Products Co., Ltd. Description and Major Businesses
Table 119. Chengdu Kanghua Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Chengdu Kanghua Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Chengdu Kanghua Biological Products Co., Ltd. Recent Developments
Table 122. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Company Information
Table 123. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Description and Major Businesses
Table 124. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 125. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. Recent Developments
Table 127. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Company Information
Table 128. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Description and Major Businesses
Table 129. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 130. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Zhejiang Tianyuan Biopharmaceutical Co., Ltd. Recent Developments
Table 132. Beijing Institute of Biological Products Co., Ltd. Company Information
Table 133. Beijing Institute of Biological Products Co., Ltd. Description and Major Businesses
Table 134. Beijing Institute of Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 135. Beijing Institute of Biological Products Co., Ltd. Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Beijing Institute of Biological Products Co., Ltd. Recent Developments
Table 137. CanSino Biological Co., Ltd. Company Information
Table 138. CanSino Biological Co., Ltd. Description and Major Businesses
Table 139. CanSino Biological Co., Ltd. Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 140. CanSino Biological Co., Ltd. Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. CanSino Biological Co., Ltd. Recent Developments
Table 142. Hualan Biological Vaccine Co., Ltd. Company Information
Table 143. Hualan Biological Vaccine Co., Ltd. Description and Major Businesses
Table 144. Hualan Biological Vaccine Co., Ltd. Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 145. Hualan Biological Vaccine Co., Ltd. Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Hualan Biological Vaccine Co., Ltd. Recent Developments
Table 147. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Company Information
Table 148. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Description and Major Businesses
Table 149. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Quadrivalent Meningococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 150. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Quadrivalent Meningococcal Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Amy Weixin Biopharmaceutical (Zhejiang) Co., Ltd. Recent Developments
Table 152. Key Raw Materials Lists
Table 153. Raw Materials Key Suppliers Lists
Table 154. Quadrivalent Meningococcal Vaccine Distributors List
Table 155. Quadrivalent Meningococcal Vaccine Customers List
Table 156. Quadrivalent Meningococcal Vaccine Market Trends
Table 157. Quadrivalent Meningococcal Vaccine Market Drivers
Table 158. Quadrivalent Meningococcal Vaccine Market Challenges
Table 159. Quadrivalent Meningococcal Vaccine Market Restraints
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
List of Figures
Figure 1. Quadrivalent Meningococcal Vaccine Product Picture
Figure 2. Global Quadrivalent Meningococcal Vaccine Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Quadrivalent Meningococcal Vaccine Market Share by Type in 2024 & 2034
Figure 4. Polysaccharide Vaccine Product Picture
Figure 5. Conjugate Vaccine Product Picture
Figure 6. Global Quadrivalent Meningococcal Vaccine Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 7. Global Quadrivalent Meningococcal Vaccine Market Share by Application in 2024 & 2034
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Quadrivalent Meningococcal Vaccine Report Years Considered
Figure 11. Global Quadrivalent Meningococcal Vaccine Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 12. Global Quadrivalent Meningococcal Vaccine Revenue 2018-2034 (US$ Million)
Figure 13. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 14. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Region (2018-2034)
Figure 15. Global Quadrivalent Meningococcal Vaccine Sales 2018-2034 ((K Units)
Figure 16. Global Quadrivalent Meningococcal Vaccine Sales Market Share by Region (2018-2034)
Figure 17. US & Canada Quadrivalent Meningococcal Vaccine Sales YoY (2018-2034) & (K Units)
Figure 18. US & Canada Quadrivalent Meningococcal Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 19. Europe Quadrivalent Meningococcal Vaccine Sales YoY (2018-2034) & (K Units)
Figure 20. Europe Quadrivalent Meningococcal Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 21. China Quadrivalent Meningococcal Vaccine Sales YoY (2018-2034) & (K Units)
Figure 22. China Quadrivalent Meningococcal Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Asia (excluding China) Quadrivalent Meningococcal Vaccine Sales YoY (2018-2034) & (K Units)
Figure 24. Asia (excluding China) Quadrivalent Meningococcal Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Sales YoY (2018-2034) & (K Units)
Figure 26. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 27. The Quadrivalent Meningococcal Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2024
Figure 28. The Top 5 and 10 Largest Manufacturers of Quadrivalent Meningococcal Vaccine in the World: Market Share by Quadrivalent Meningococcal Vaccine Revenue in 2024
Figure 29. Global Quadrivalent Meningococcal Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 30. Global Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2034)
Figure 31. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Type (2018-2034)
Figure 32. Global Quadrivalent Meningococcal Vaccine Sales Market Share by Application (2018-2034)
Figure 33. Global Quadrivalent Meningococcal Vaccine Revenue Market Share by Application (2018-2034)
Figure 34. US & Canada Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2034)
Figure 35. US & Canada Quadrivalent Meningococcal Vaccine Revenue Market Share by Type (2018-2034)
Figure 36. US & Canada Quadrivalent Meningococcal Vaccine Sales Market Share by Application (2018-2034)
Figure 37. US & Canada Quadrivalent Meningococcal Vaccine Revenue Market Share by Application (2018-2034)
Figure 38. US & Canada Quadrivalent Meningococcal Vaccine Revenue Share by Country (2018-2034)
Figure 39. US & Canada Quadrivalent Meningococcal Vaccine Sales Share by Country (2018-2034)
Figure 40. U.S. Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 41. Canada Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 42. Europe Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2034)
Figure 43. Europe Quadrivalent Meningococcal Vaccine Revenue Market Share by Type (2018-2034)
Figure 44. Europe Quadrivalent Meningococcal Vaccine Sales Market Share by Application (2018-2034)
Figure 45. Europe Quadrivalent Meningococcal Vaccine Revenue Market Share by Application (2018-2034)
Figure 46. Europe Quadrivalent Meningococcal Vaccine Revenue Share by Country (2018-2034)
Figure 47. Europe Quadrivalent Meningococcal Vaccine Sales Share by Country (2018-2034)
Figure 48. Germany Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 49. France Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 50. U.K. Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 51. Italy Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 52. Russia Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 53. China Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2034)
Figure 54. China Quadrivalent Meningococcal Vaccine Revenue Market Share by Type (2018-2034)
Figure 55. China Quadrivalent Meningococcal Vaccine Sales Market Share by Application (2018-2034)
Figure 56. China Quadrivalent Meningococcal Vaccine Revenue Market Share by Application (2018-2034)
Figure 57. Asia Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2034)
Figure 58. Asia Quadrivalent Meningococcal Vaccine Revenue Market Share by Type (2018-2034)
Figure 59. Asia Quadrivalent Meningococcal Vaccine Sales Market Share by Application (2018-2034)
Figure 60. Asia Quadrivalent Meningococcal Vaccine Revenue Market Share by Application (2018-2034)
Figure 61. Asia Quadrivalent Meningococcal Vaccine Revenue Share by Region (2018-2034)
Figure 62. Asia Quadrivalent Meningococcal Vaccine Sales Share by Region (2018-2034)
Figure 63. Japan Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 64. South Korea Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 65. China Taiwan Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 66. Southeast Asia Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 67. India Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 68. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Sales Market Share by Type (2018-2034)
Figure 69. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue Market Share by Type (2018-2034)
Figure 70. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Sales Market Share by Application (2018-2034)
Figure 71. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue Market Share by Application (2018-2034)
Figure 72. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Revenue Share by Country (2018-2034)
Figure 73. Middle East, Africa and Latin America Quadrivalent Meningococcal Vaccine Sales Share by Country (2018-2034)
Figure 74. Brazil Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 75. Mexico Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 76. Turkey Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 77. Israel Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 78. GCC Countries Quadrivalent Meningococcal Vaccine Revenue (2018-2034) & (US$ Million)
Figure 79. Quadrivalent Meningococcal Vaccine Value Chain
Figure 80. Quadrivalent Meningococcal Vaccine Production Process
Figure 81. Channels of Distribution
Figure 82. Distributors Profiles
Figure 83. Bottom-up and Top-down Approaches for This Report
Figure 84. Data Triangulation
Figure 85. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries